Arrowhead Pharmaceuticals Applies to New Zealand Regulator for Trial of ARO-DIMER-PA to Treat Mixed Hyperlipidemia

MT Newswires Live

昨天

Arrowhead Pharmaceuticals (ARWR) said Tuesday it has requested regulatory clearance from New Zealand's Medicines and Medical Devices Safety Authority to conduct a phase 1/2a clinical trial of ARO-DIMER-PA to treat patients with atherosclerotic cardiovascular disease due to mixed hyperlipidemia.

Mixed hyperlipidemia patients have elevated low-density lipoprotein cholesterol and triglyceride levels, a major risk factor for atherosclerotic cardiovascular disease, the company said, adding that it is the leading cause of death in the world.

The company said the trial, if approved, will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects of ARO-DIMER-PA on low-density lipoprotein cholesterol and triglyceride levels.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573493957"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573493957\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573493957?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573493957","market":"us","top_or_hot":-1,"title":"Arrowhead Pharmaceuticals Applies to New Zealand Regulator for Trial of ARO-DIMER-PA to Treat Mixed Hyperlipidemia","media":"MT Newswires Live","content":"<html><body><p> Arrowhead Pharmaceuticals (ARWR) said Tuesday it has requested regulatory clearance from <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a>'s Medicines and Medical Devices Safety Authority to conduct a phase 1/2a clinical trial of ARO-DIMER-PA to treat patients with atherosclerotic cardiovascular disease due to mixed hyperlipidemia.</p><p>Mixed hyperlipidemia patients have elevated low-density lipoprotein cholesterol and triglyceride levels, a major risk factor for atherosclerotic cardiovascular disease, the company said, adding that it is the leading cause of death in the world.</p><p>The company said the trial, if approved, will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects of ARO-DIMER-PA on low-density lipoprotein cholesterol and triglyceride levels.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Pharmaceuticals Applies to New Zealand Regulator for Trial of ARO-DIMER-PA to Treat Mixed Hyperlipidemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Pharmaceuticals Applies to New Zealand Regulator for Trial of ARO-DIMER-PA to Treat Mixed Hyperlipidemia\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-07 20:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Arrowhead Pharmaceuticals (ARWR) said Tuesday it has requested regulatory clearance from <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a>'s Medicines and Medical Devices Safety Authority to conduct a phase 1/2a clinical trial of ARO-DIMER-PA to treat patients with atherosclerotic cardiovascular disease due to mixed hyperlipidemia.</p><p>Mixed hyperlipidemia patients have elevated low-density lipoprotein cholesterol and triglyceride levels, a major risk factor for atherosclerotic cardiovascular disease, the company said, adding that it is the leading cause of death in the world.</p><p>The company said the trial, if approved, will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects of ARO-DIMER-PA on low-density lipoprotein cholesterol and triglyceride levels.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NZ20C.NZ","symbol_name":"S&P/NZX 20","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2573493957","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573493957","pubTimestamp":1759840032,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arrowhead Pharmaceuticals (ARWR) said Tuesday it has requested regulatory clearance from New Zealand's Medicines and Medical Devices Safety Authority to conduct a phase 1/2a clinical trial of ARO-DIME","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NZ20C.NZ":"S&P/NZX 20","NZ50G.NZ":"S&P/NZX 50","BK4588":"碎股","ARWR":"Arrowhead Research Corporation","BK4585":"ETF&股票定投概念","T10G.NZ":"S&P/NZX 10","BK4139":"生物科技"},"translate_title":"Arrowhead Pharmaceuticals向新西兰监管机构申请ARO-DIMER-PA治疗混合型高脂血症的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1.5,"NZ20C.NZ":1.5,"NZ50G.NZ":1.5,"T10G.NZ":1.5},"content_text":"Arrowhead Pharmaceuticals (ARWR) said Tuesday it has requested regulatory clearance from New Zealand's Medicines and Medical Devices Safety Authority to conduct a phase 1/2a clinical trial of ARO-DIMER-PA to treat patients with atherosclerotic cardiovascular disease due to mixed hyperlipidemia.Mixed hyperlipidemia patients have elevated low-density lipoprotein cholesterol and triglyceride levels, a major risk factor for atherosclerotic cardiovascular disease, the company said, adding that it is the leading cause of death in the world.The company said the trial, if approved, will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects of ARO-DIMER-PA on low-density lipoprotein cholesterol and triglyceride levels.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}